Synergistic effect of ginsenoside Rg3 with verapamil on the modulation of multidrug resistance in human acute myeloid leukemia cells

April 2014
Oncology Letters;2014, Vol. 7 Issue 4, p1265
Academic Journal
The pharmacological modulatory effects of 20(S)-ginsenoside Rg3 (20S-Rg3) on multidrug resistant cancer cells are reported in the present study. The effects of 20(S)-Rg3 on the modulation of doxorubicin (DOX) and vincristine (VCR) resistance were examined in the HL60 multidrug resistant subline of human acute myeloid leukemia cells. Results demonstrated that 20S-Rg3 is as effective as verapamil (Vp) for modulating the high degree primary DOX resistance and low degree VCR cross-resistance expressed by the H160 cell line. Furthermore, the present study demonstrates for the first time, using isobologram analysis, that the combination of 20S-Rg3 and Vp enhances the reversal of DOX and VCR resistance in a supra-additive or at least an additive manner. These results indicate that 20S-Rg3 may be used as a Vp synergizer or as a promising alternative to Vp in the chemosensitization of multidrug resistant acute myeloid leukemia, with far fewer side effects.


Related Articles

  • Effect of CD38 on the multidrug resistance of human chronic myelogenous leukemia K562 cells to doxorubicin. YALÇINTEPE, LEMAN; HALIS, EMRE; ULKU, SIBEL // Oncology Letters;Mar2016, Vol. 11 Issue 3, p2290 

    Drug resistance is a serious challenge in cancer chemotherapy. Alterations in the intracellular concentration and homeostasis of calcium (Ca2+) may contribute to the development of drug resistance. To investigate the mechanism of drug resistance in leukemia, the present study rendered human...

  • The glutathione S-transferase inhibitor 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol overcomes the MDR1-P-glycoprotein and MRP1-mediated multidrug resistance in acute myeloid leukemia cells. Ascione, Alessandro; Cianfriglia, Maurizio; Dupuis, Maria Luisa; Mallano, Alessandra; Sau, Andrea; Tregno, Francesca Pellizzari; Pezzola, Silvia; Caccuri, Anna Maria // Cancer Chemotherapy & Pharmacology;Jul2009, Vol. 64 Issue 2, p419 

    There has been an ever growing interest in the search for new anti-tumor compounds that do not interact with MDR1-Pgp and MRP1 drug transporters and so circumvent the effect of these proteins conferring multidrug resistance (MDR) and poor prognosis in AML patients. We have investigated the...

  • Inhibition of STAT3-interacting protein 1 (STATIP1) promotes STAT3 transcriptional up-regulation and imatinib mesylate resistance in the chronic myeloid leukemia. Mencalha, André L.; Corrêa, Stephany; Salles, Daniela; Du Rocher, Bárbara; Santiago, Marcelo F.; Abdelhay, Eliana // BMC Cancer;2014, Vol. 14 Issue 1, p1 

    Background Signal transducer and activator of transcription 3 (STAT3) is an important transcriptional factor frequently associated with the proliferation and survival of a large number of distinct cancer types. However, the signaling pathways and mechanisms that regulate STAT3 activation remain...

  • Biology: Three known unknowns. Bourzac, Katherine // Nature;5/29/2014, Vol. 509 Issue 7502, pS69 

    The article focuses on the role of drug imatinib for treatment of chronic myeloid leukaemia (CML) and the questions about drug resistant in cancer cells, cancer spread and role of normal tissue in cancer. Topics discussed include early clinical trails for the drug designed by clinical oncologist...

  • Blocking programmed cell death 1 in combination with adoptive cytotoxic T-cell transfer eradicates chronic myelogenous leukemia stem cells. Riether, C; Gschwend, T; Huguenin, A-L; Schürch, C M; Ochsenbein, A F // Leukemia (08876924);Aug2015, Vol. 29 Issue 8, p1781 

    The authors discuss a study on the expression of programmed cell death ligand 1 (PD-L1) in the differentiation hierarchy of bone marrow (BM) chronic myelogenous leukemia (CML) stem/progenitor cell subsets. Topics covered include the resistance of self-renewing leukemia stem cells (LSC) against...

  • Retinoic Acid Therapy Resistance Progresses from Unilineage to Bilineage in HL-60 Leukemic Blasts. Jensen, Holly A.; Bunaciu, Rodica P.; Ibabao, Christopher N.; Myers, Rebecca; Varner, Jeffrey D.; Yen, Andrew // PLoS ONE;Jun2014, Vol. 9 Issue 6, p1 

    Emergent resistance can be progressive and driven by global signaling aberrations. All-trans retinoic acid (RA) is the standard therapeutic agent for acute promyelocytic leukemia, but 10–20% of patients are not responsive, and initially responsive patients relapse and develop retinoic...

  • The sonic hedgehog factor GLI1 imparts drug resistance through inducible glucuronidation. Zahreddine, Hiba Ahmad; Culjkovic-Kraljacic, Biljana; Assouline, Sarit; Gendron, Patrick; Romeo, Andrea A.; Morris, Stephen J.; Cormack, Gregory; Jaquith, James B.; Cerchietti, Leandro; Cocolakis, Eftihia; Amri, Abdellatif; Bergeron, Julie; Leber, Brian; Becker, Michael W.; Pei, Shanshan; Jordan, Craig T.; Miller, Wilson H.; Borden, Katherine L. B. // Nature;7/3/2014, Vol. 511 Issue 7507, p90 

    Drug resistance is a major hurdle in oncology. Responses of acute myeloid leukaemia (AML) patients to cytarabine (Ara-C)-based therapies are often short lived with a median overall survival of months. Therapies are under development to improve outcomes and include targeting the eukaryotic...

  • Characterization of a multidrug-resistant chronic myeloid leukemia cell line presenting multiple resistance mechanisms. Daflon-Yunes, Nathalia; Pinto-Silva, Flavio; Vidal, Raphael; Novis, Bruna; Berguetti, Tandressa; Lopes, Raphael; Polycarpo, Carla; Rumjanek, Vivian // Molecular & Cellular Biochemistry;Nov2013, Vol. 383 Issue 1/2, p123 

    The multidrug-resistant (MDR) phenotype is multifactorial, and cell lines presenting multiple resistance mechanisms might be good models to understand the importance of the various pathways involved. The present work characterized a MDR chronic myeloid leukemia cell line, derived from K562...

  • Ariad's drug effective in certain leukemia treatment.  // PharmaWatch: Cancer;May 2004, Vol. 3 Issue 5, p20 

    Reports that Ariad Pharmaceuticals Inc.'s lead product candidate, AP23464, has demonstrated its effectiveness in blocking the growth of leukemia cells that harbor mutations in the Abl protein that confer resistance to Gleevec, a primary treatment for chronic myelogenous leukemia (CML). Details...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics